These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36325957)

  • 1. Clinical and molecular characteristics of kinase domain duplications across diverse cancer types in the Chinese population.
    Lai X; Yu R; Ou Q; Bao H; Wu X; Shao Y; Li Y; Zhang Y; Ding Q
    Cancer Med; 2023 Mar; 12(5):6009-6015. PubMed ID: 36325957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The landscape of kinase domain duplication in Chinese lung cancer patients.
    Wu D; Xie Y; Jin C; Qiu J; Hou T; Du H; Chen S; Xiang J; Shi X; Liu J
    Ann Transl Med; 2020 Dec; 8(24):1642. PubMed ID: 33490154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC.
    Wang J; Li X; Xue X; Ou Q; Wu X; Liang Y; Wang X; You M; Shao YW; Zhang Z; Zhang S
    Int J Cancer; 2019 Jun; 144(11):2677-2682. PubMed ID: 30255937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.
    Gallant JN; Sheehan JH; Shaver TM; Bailey M; Lipson D; Chandramohan R; Red Brewer M; York SJ; Kris MG; Pietenpol JA; Ladanyi M; Miller VA; Ali SM; Meiler J; Lovly CM
    Cancer Discov; 2015 Nov; 5(11):1155-63. PubMed ID: 26286086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular diagnosis and clinical outcome of a lung cancer patient with
    Yang D; Han X; Li D; Cui S; Liu S; Wu X; Dai Z
    Am J Transl Res; 2020; 12(10):6689-6693. PubMed ID: 33194065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting.
    Du Z; Brown BP; Kim S; Ferguson D; Pavlick DC; Jayakumaran G; Benayed R; Gallant JN; Zhang YK; Yan Y; Red-Brewer M; Ali SM; Schrock AB; Zehir A; Ladanyi M; Smith AW; Meiler J; Lovly CM
    Nat Commun; 2021 Mar; 12(1):1382. PubMed ID: 33654076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
    Shigematsu H; Lin L; Takahashi T; Nomura M; Suzuki M; Wistuba II; Fong KM; Lee H; Toyooka S; Shimizu N; Fujisawa T; Feng Z; Roth JA; Herz J; Minna JD; Gazdar AF
    J Natl Cancer Inst; 2005 Mar; 97(5):339-46. PubMed ID: 15741570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the EGFR-KDD mutation as a possible mechanism of acquired resistance of non-small cell lung cancer to EGFR tyrosine kinase inhibitors: A case report.
    He C; Wang Y
    Mol Clin Oncol; 2022 Feb; 16(2):30. PubMed ID: 34987800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung Adenocarcinoma Harboring
    Li J; Yan J; Cao R; Du G; Zhao G
    Front Oncol; 2020; 10():575739. PubMed ID: 33392076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung Adenocarcinoma Patient Harboring
    Zhao L; Wang Z; Du H; Chen S; Wang P
    Front Oncol; 2021; 11():605853. PubMed ID: 33898306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep Targeted Sequencing and Its Potential Implication for Cancer Therapy in Chinese Patients with Gastric Adenocarcinoma.
    Yu P; Wang Y; Yu Y; Wang A; Huang L; Zhang Y; Liu W; Wu H; Yao M; Du YA; Cheng X
    Oncologist; 2021 May; 26(5):e756-e768. PubMed ID: 33511732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and molecular characteristics of Chinese non-small cell lung cancer patients with ERBB2 transmembrane domain mutations.
    Fan Y; Qiu J; Yu R; Cao R; Chen X; Ou Q; Wu X; Shao YW; Nagasaka M; Zhang J; Ou SI
    Mol Oncol; 2020 Aug; 14(8):1731-1739. PubMed ID: 32478891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an
    Chen D; Li XL; Wu B; Zheng XB; Wang WX; Chen HF; Dong YY; Xu CW; Fang MY
    Front Oncol; 2020; 10():867. PubMed ID: 32656077
    [No Abstract]   [Full Text] [Related]  

  • 15. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
    Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O
    Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infantile fibrosarcoma with an EGFR kinase domain duplication: Underlining a close relationship with congenital mesoblastic nephroma and highlighting a similar morphological spectrum.
    van Spronsen R; Kester LA; Knops RRG; van de Sande MAJ; van Leenders GJLH; de Laat PCJ; Stortelder E; Korpershoek E; van Noesel MM; Meister MT; Koerkamp MJAG; de Graaf N; Giovannoni I; Tops BBJ; de Krijger RR; Ter Horst SAJ; Flucke U; Alaggio R; Hiemcke-Jiwa LS
    Ann Diagn Pathol; 2022 Apr; 57():151885. PubMed ID: 35032896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients.
    Liu L; Liu J; Shao D; Deng Q; Tang H; Liu Z; Chen X; Guo F; Lin Y; Mao M; Kristiansen K; Ye M; He J
    Cancer Sci; 2017 Dec; 108(12):2487-2494. PubMed ID: 28949084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic and epigenetic alterations of the LKB1 gene and their associations with mutations in TP53 and EGFR pathway genes in Korean non-small cell lung cancers.
    Lee SM; Choi JE; Na YK; Lee EJ; Lee WK; Choi YY; Yoon GS; Jeon HS; Kim DS; Park JY
    Lung Cancer; 2013 Aug; 81(2):194-9. PubMed ID: 23664447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.
    Hu W; Liu Y; Chen J
    Oncotarget; 2017 Apr; 8(15):25046-25054. PubMed ID: 28212572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
    VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
    Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.